Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

BACKGROUND: Chk1 inhibitors have emerged as promising anticancer therapeutic agents particularly when combined with antimetabolites such as gemcitabine, cytarabine or hydroxyurea. Here, we address the importance of appropriate drug scheduling when gemcitabine is combined with the Chk1 inhibitor MK-8...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Montano, Ryan, Thompson, Ruth, Chung, Injae, Hou, Huagang, Khan, Nadeem, Eastman, Alan
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2013
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3878047/
https://ncbi.nlm.nih.gov/pubmed/24359526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-604
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky